Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplantation

Seventy-five percent of patients treated with hematopoietic stem cell transplants survive one-year post-transplantation. However, this intensive treatment is associated with prolonged hospitalizations and significant deconditioning. Pathophysiological changes in skeletal muscle mass and function have notable implications for disease progression and long-term prognosis. Patients frequently report substantial rehabilitation needs, though these needs are highly individualized and fluctuate over time, with musculoskeletal dysfunction and fa-tigue being the most common barriers to prehabilitation. Furthermore, at least 35% of cancer patients are found to have inadequate daily protein intake, which may hinder improve-ments in physical performance through prehabilitation. Several recent studies have demonstrated the safety and feasibility of exercise-based prehabilitation interventions during the pre-transplant period. However, no full-scale randomized controlled trial (RCT) has been conducted to date.

NCT Number	NCT07341698
Lead Sponsor	Rigshospitalet, Denmark Collaborators: Aarhus University Hospital
Conditions	Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Enrollment	110 participants
Start Date	2026-01-12
Primary Completion	2028-01-12 (estimated)
Study Completion	2032-10-12 (estimated)
Updated on ClinicalTrials.gov	2026-01-29